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Abstract
Previous studies have shown that apolipoprotein E (apoE) plays a role in immune function by modulating tissue redox
balance. Using a mouse macrophage cell line (RAW 264.7), we have examined the mechanism by which apoE regulates nitric
oxide (NO) production in macrophages. ApoE potentiates NO production in immune activated RAW cells in combination
with lipopolysaccharide or polyinosinic:polycytidylic acid (PIC), agents known to induce expression of inducible nitric oxide
synthase mRNA and protein. The effect is not observed with apolipoprotein B or heat-inactivated apoE. The combination of
PIC plus apoE produced more NO than the level expected from an additive effect of PIC and apoE alone. Furthermore, this
increase was observed at submaximal extracellular arginine concentrations, suggesting that apoE altered arginine (substrate)
availability. Examination of [3H]arginine uptake across the cell membrane demonstrated that arginine uptake was increased
by PIC but further increased by PIC plus apoE. Treatment of RAW cells with apoE was associated with an increased
apparent Vmax and decreased affinity for arginine as well as a switch in the induction of mRNA for subtypes of cationic
amino acid transporters (CAT). Treatment of RAW cells with PIC plus apoE resulted in the loss of detectable CAT1 mRNA
and expression of CAT2 mRNA. Regulation of arginine availability is a novel action of apoE on the regulation of
macrophage function and the immune response. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Apolipoprotein E (apoE) is the protein component
of a lipid-protein complex and is a member of a
larger family of apoproteins that transports lipids
throughout the body. Although apoE is found in
plasma, it is a primary component of lipid and cho-
lesterol metabolism in the central nervous system
(CNS) and is particularly important during synthesis
and repair of glial and neuronal membranes. ApoE
expression is increased during the response of the
CNS to injury and has been observed to promote
neuron sprouting [1^5]. The function of apoE in neu-
ronal injury and repair, however, extends beyond
regulation of lipid transport and the supply of lipids
for membrane reconstruction. Previous studies have
demonstrated that apolipoproteins can alter the tis-
sue redox balance. Miyata and Smith [6] have shown
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that apoE serves as a direct antioxidant and can
protect cells from oxy radical-mediated damage.
Furthermore, mice lacking apoE (APOE3/3) dem-
onstrated decreased antioxidant levels and decreased
recovery after head injury [7]. We have shown that
apoE increased the production of nitric oxide
(NO) from human monocyte-derived macrophages
(MDM) [8]. Macrophages are a major cellular source
of NO and are stimulated to produce NO and other
reactive oxygen species by proin£ammatory factors
[9^11]. These reactive species are part of the innate
immune response mediated by macrophages during
tissue in£ammation and injury [11^14]. Thus, apoE-
mediated regulation of NO may be an important link
between tissue redox balance and in£ammation. The
link between NO and apoE may also have clinical
relevance since chronic neurodegenerative diseases
such as Alzheimer’s disease (AD) involve in£amma-
tion and oxidative stress [15^19]. Furthermore, Roses
[5] and colleagues [20,21] have demonstrated an in-
creased susceptibility to AD in individuals expressing
the APOE4 allele.
Using a macrophage cell line (RAW 264.7) we
have more fully examined the speci¢c factors that
regulate the e¡ect of apoE on NO production.
RAW 264.7 cells have been well characterized as a
model for macrophage function and share functional
homology with other tissue macrophages including
the CNS macrophage, the microglia [13,22,23].
Thus, these cells can be used as a model for micro-
glia. Our new data demonstrate a novel action of
apoE on the regulation of macrophage function
and the immune response.
2. Methods
2.1. Materials
Delipidated apoE puri¢ed from human serum was
obtained from Chemicon International (Temcula,
CA) or ICN Pharmaceuticals (Costa Mesa, CA)
and used immediately on dilution. Since mixed hu-
man serum was the source of this apoE and since
approx. 84% of the population carries the APOE 3
allele [24], it is likely that apoE3 is the predominant
isoform in this source. Recombinant human apoE3
purchased from commercial sources was found to be
unstable in our cultures and was not used in this
study. Human apoE3 was also isolated from serum-
free conditioned medium (CM) of primary astrocyte
cultures of mice made transgenic for human apoE3
on a mouse apoE knockout background and was a
generous gift from Dr. David Holtzman and Dr.
Ron DeMattos (Washington University School of
Medicine, St. Louis, MO). Conditioned medium (3
days) from the transgenic apoE3 or apoE4 astrocyte
cultures was sterile ¢ltered and circulated over a
monoclonal antibody column at 4‡C for 16 h. After
washing with 200 ml PBS, apoE was eluted with 3 M
sodium thiocyanate and dialyzed extensively against
PBS containing 0.01% azide. The particles were then
characterized by apoE ELISA, Western, Coomassie,
and non-denaturing gradient gels. The fully charac-
terized stock solution was diluted approx. 1/1000
into normal medium, thus the azide concentration
was considered to be negligible. Delipidated apolipo-
protein B puri¢ed from human serum was purchased
from Chemicon. Polyinosinic acid:polycytidylic acid
(PIC) (K salt) was purchased from Sigma (St.
Louis, MO). Lipopolysaccharide (LPS; O55:B5)
was obtained from Calbiochem (San Diego, CA)
and recombinant murine interferon-Q (IFNQ) was ob-
tained from Gibco (Rockville, MD). The inducible
nitric oxide synthase (iNOS) antibody (#06-295)
was purchased from Upstate Biotechnology (Lake
Placid, NY). Normal tissue culture medium and sup-
plements were purchased from Gibco while arginine-
free DMEM was purchased from ICN.
2.2. Cultures
The mouse macrophage cell line (RAW 264.7) was
obtained from ATCC (Reston, VA) and cultured in
DMEM containing 10% heat-inactivated fetal calf
serum (FCS), 2 mM glutamine, 100 U/ml pen-strep
and 15 mM HEPES bu¡er. Cells were grown in a
humidi¢ed 95% air, 5% oxygen atmosphere at 37‡C
until con£uent. Prior to the experiment, the cells
were removed from the £ask by trypsinization,
spun at 1000Ug to pellet and resuspended in growth
medium. The cells were plated into the center wells
of 96-well dishes at an initial density of 40 000 cells
per well and allowed to recover overnight. In some
cases, an increased number of cells were plated into
six-well dishes for PCR or Western blot analysis.
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2.3. NO assay
Nitric oxide production was measured from the
supernatant levels of nitrite, the stable biological ox-
idation product of NO, using the Griess reaction as
described previously [25,26] or a Seivers nitric oxide
analyzer (NOA 280, Seivers Instrument, Boulder,
CO) which detects the chemiluminescent signal gen-
erated by the reaction of nitric oxide with ozone.
RAW cells plated as described above were treated
with 100 U/ml recombinant murine IFNQ in normal
growth medium (IFNQ-primed) or remained un-
treated (non-primed). After 8^12 h of pretreatment
the medium was replaced with serum-free medium
containing the experimental agents for an additional
4^24 h. Cell supernatants were then collected and the
nitrite levels determined using sodium nitrite as the
standard. The protein content of the wells was ob-
tained using the Pierce BCA assay (Rockford, IL)
with bovine serum albumin as the standard. Data
are presented as Wmoles of nitrite/40 000 cells or as
Wmoles of nitrite/Wg protein. Two to six wells of cells
were assayed per experimental condition for at least
three di¡erent culture groups. Statistical analysis was
done using an ANOVA with the Bonferroni correc-
tion or using the unpaired Student’s t-test.
2.4. Arginine uptake
RAW cells were plated into 96-well plates (approx.
8U104 cells per well) and allowed to adhere over-
night. Cells were then primed with IFNQ (100
U/ml) for 8^12 h in cell culture medium. After the
pretreatment, the culture medium was aspirated and
discarded. The cells were then treated for an addi-
tional 4 h with fresh serum-free medium containing
10 WM arginine plus the various treatment condi-
tions. This value of arginine was chosen because it
more closely represents extracellular arginine levels in
the CNS [27]. After the 4 h, medium was either dis-
carded or saved for nitrite analysis. The cells were
washed with warm (37‡C) uptake bu¡er containing
in mM: NaCl, 137; KCl, 2.7; CaCl2, 1.5; KH2PO4,
1.2; MgSO4, 1.0; HEPES, 20; adjusted to pH 7.4.
L-[3H]Arginine (1 Ci/ml, New England Nuclear) up-
take was measured by incubating the cell monolayers
for 5 min at 37‡C in the presence of increasing con-
centrations of unlabeled L-arginine (1^100 WM).
After the 5 min incubation, the plate was inverted
to remove any bu¡er containing excess tracer, and
placed on a tray of melting ice. Ice-cold bu¡er con-
taining 10 mM unlabeled substrate was then added
(0.1 ml). The bu¡er was removed by inversion of the
plate and blotting on a paper towel. The washing
procedure was repeated twice more for a total of
three washes. Radioactivity in 1.0% Triton X-100
extracts was then determined by liquid scintillation
counting. Non-speci¢c uptake of L-[3H]arginine was
found by repeating the above procedures at 4‡C.
Values of non-speci¢c uptake at 4‡C were subtracted
from the values at 37‡C. A portion of the cell digest
was used for protein measurement (Pierce BCA as-
say). Uptake (cpm/mg protein) was then calculated
and data are expressed as the average percent change
from the non-primed, untreated control. Statistical
analysis was done using an unpaired Student’s t-test.
2.5. Western blot analysis
Cell lysates from treated and untreated RAW cells
were analyzed by Western blot for immunoreactivity
to iNOS. Protein concentration of each cell lysate
sample was determined using the Pierce BCA assay.
Sample bu¡er was then added to equal protein con-
centrations from the cell samples and the mixtures
boiled for 5 min. These samples were loaded onto
pre-cast gradient gels, electrophoresed for 1 h at con-
stant voltage and then transferred to nitrocellulose
for 1 h. After blocking (Blotto), the primary anti-
body was applied overnight at 4‡C followed by wash-
ing in three changes of PBS and then a single wash of
Blotto. The appropriate biotinylated secondary anti-
body was applied for 1 h, the blot washed and then
incubated with extravidin peroxidase. Location of
immunoreactive bands was detected by enhanced
chemiluminescence (ECL) (Amersham, Newark,
NJ) per manufacturer’s instructions. Biotinylated
molecular weight standards were used to identify
the approximate size of the immunoreactive bands
for each Western blot.
2.6. RT-PCR
Total RNA was prepared from treated or un-
treated RAW cells using the TRizol reagent (Gibco)
according to the manufacturer’s protocol. Total
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RNA was reversed-transcribed using Thermoscript
RT (Gibco) with speci¢c antisense oligonucleotides
TTATTCTGGGTCTCAGGGGCTGAAG and CG-
CTTTATCTTCTGGCTGCTGGTC (for mCAT1),
GCGTTTGAGTATGTCAGATGGGGC and AG-
GCATCCTCATCGTCTTCTTCGTC (for mCAT2)
and GACCATGAGTGAATCCAACGGCAC and
TACGGCAAGCAGTAGGGAGCAAAC (for
mCAT3). Conditions for PCR ampli¢cation of the
resulting ¢rst-strand DNA template were 95‡C (de-
naturing), 64‡C (annealing), 72‡C (extension) for
25 cycles using platinum Taq DNA polymerase
(5 U/ml) and 1.8 mM MgSO4. PCR products were
sequenced to con¢rm their identity.
Relative values for mRNA expression were ob-
tained by densitometry (NIH Image) of PCR prod-
ucts separated on polyacrylamide gradient gels,
stained with ethidium bromide and viewed under ul-
traviolet light. The ratios of experimental bands to
corresponding control (L-actin) bands were used as a
relative measurement of gene expression. For each
gene, ratiometric data for each triplicate group per
Fig. 1. (A) The e¡ect of apoE on non-primed (resting) and interferon-Q (IFNQ)-primed RAW cells. RAW cells were either pretreated
with 100 U/ml recombinant murine IFNQ for 12 h in normal growth medium or remained untreated. The medium was then replaced
with serum-free medium containing varying concentrations of apoE (10^100 nM) for an additional 24 h. Data points represent the
average þ S.E.M. supernatant nitrite value (Wmoles/40 000 cells) for a minimum of three wells for four di¡erent culture groups.
*P6 0.05 level compared to IFNQ priming only (ANOVA). (B) ApoE-stimulated production of NO is increased with increasing doses
of IFNQ. RAW cells were pretreated with growth medium containing 10^1000 U/ml IFNQ for 12 h or remained untreated. The me-
dium was then replaced with serum-free medium containing 50 nM apoE and supernatant nitrite levels were measured at 24 h. Data
points represent the average þ S.E.M. nitrite value (Wmoles/40 000 cells). n = at least 12 wells assayed per experimental condition.
*P6 0.003 compared to IFNQ alone.
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experimental condition were averaged. Statistical dif-
ferences were determined using an unpaired Stu-
dent’s t-test.
3. Results
RAW 264.7 cells, a mouse macrophage clonal cell
line, generate NO when stimulated by factors asso-
ciated with tissue injury and in£ammation. To deter-
mine the e¡ect of apoE on the production of NO by
RAW cells, we treated non-primed (resting) and
IFNQ-primed cells with apoE. The resultant NO pro-
duction was determined by detecting nitrite concen-
trations in the cell supernatants. As shown in Fig.
1A, apoE had no e¡ect on NO production in resting
(non-primed) RAW cells. However, when RAW cells
were primed for 12 h with recombinant murine IFNQ
and then treated with apoE, NO production was in-
creased compared to non-primed conditions. ApoE
increased NO production in a dose-dependent fash-
ion up to 100 nM, the maximal apoE concentration
studied (Fig. 1A). In addition, the level of nitrite
produced by apoE was increased with increasing
Fig. 2. (A) ApoE enhanced the e¡ect of polyinosinic acid:polycytidylic acid (PIC), a double stranded polyribonucleotide, on NO pro-
duction. RAW cells were pretreated with 100 U/ml IFNQ for 12 h, followed by treatment for 24 h with serum-free medium containing
apoE alone (10^100 nM), PIC alone (0.5 Wg/ml) or PIC (0.5 Wg/ml) plus apoE (10^100 nM). Data points represent the average þ
S.E.M. supernatant nitrite value (Wmoles/40 000 cells). n = 12 wells assayed. *P6 0.001 compared to PIC by ANOVA. **P6 0.05 com-
pared to IFNQ priming alone by ANOVA. (B) Detection of immunoreactive iNOS in IFNQ-primed RAW cells treated with PIC
(0.5 Wg/ml) alone and in combination with apoE (50 nM) for 12 h. Representative Western blot from three separate experiments.
Lanes: A, non-primed cells ; B, IFNQ primed+PIC; C, IFNQ primed+PIC+apoE. Molecular weight standards from the same gel are
also shown.
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concentrations of IFNQ used in the priming process
(Fig. 1B). Enhanced production of NO was also seen
in RAW cells primed with IFNK in place of IFNQ
(data not shown), indicating that both lymphokines
could promote the e¡ect of apoE.
To determine if apoE modulated NO production
in the presence of agents known to upregulate the
expression of inducible nitric oxide synthase
(iNOS), the enzyme that catalyzes the production
of NO from arginine, we examined the e¡ect of
apoE on NO production in RAW cells treated with
PIC or LPS. Both PIC, a double stranded polyribo-
nucleotide which serves as a viral mimetic, or LPS, a
bacterial coat component, are well known to induce
iNOS mRNA and protein expression and initiate NO
production in interferon-primed macrophages
[12,28,29]. Consistent with the ability of PIC to in-
duce iNOS mRNA and protein, treatment of IFNQ-
primed RAW cells with PIC (0.5 Wg/ml) for 24 h
resulted in a signi¢cant increase in supernatant nitrite
levels compared to cells primed with IFNQ alone
(Fig. 2). The simultaneous addition of apoE and
PIC, however, signi¢cantly increased NO levels com-
pared to PIC or to apoE alone. This e¡ect of apoE
was dose-dependent and could not be explained by a
simple additive e¡ect of PIC and apoE on superna-
tant nitrite levels at each concentration of apoE. Im-
munodetection (Western blot) of iNOS protein ex-
pression was performed on cell lysates from RAW
cells treated with a non-maximal dose of PIC (0.5
Wg/ml) in the presence and absence of 50 nM apoE.
A representative blot is shown in Fig. 2B. No appar-
ent change in iNOS protein expression was seen
when PIC-treated cells were simultaneously treated
with apoE.
Enhancement of NO production by apoE was not
speci¢c to PIC since LPS-induced NO production
was also increased. Simultaneous exposure of
IFNQ-primed RAW cells to LPS (0.1 Wg/ml) and
apoE (50 nM) increased supernatant nitrite levels
compared to LPS alone (Fig. 3). Treatment of the
RAW cells with apolipoprotein B (10^100 nM), an-
other form of circulating lipoprotein, or with boiled
apoE did not increase supernatant nitrite levels.
Since apoE from plasma di¡ers from apoE derived
from the CNS [30], we tested the e¡ect of apoE
isolated from astrocytes, the primary source of
apoE in the CNS [31]. CM from primary astrocyte
cultures of human apoE3 transgenic mice was used
as a source of CNS-derived apoE3 [30,32,33]. The
apoE produced by these astrocytes has been fully
characterized and is comprised of lipid containing
particles similar to those isolated from cerebral spi-
nal £uid (CSF) [33]. RAW cells were pretreated with
100 U/ml IFNQ for 12 h and then exposed for an
additional 24 h to 0.5 Wg/ml PIPC alone or in the
presence of 50 nM apoE3 puri¢ed from astrocyte
CM (Fig. 3). Supernatant nitrite levels were signi¢-
cantly (P6 0.05) increased in the presence of astro-
cyte CM-apoE3 plus PIPC (3.3 þ 0.43 Wmoles) com-
pared to PIC alone (2.1 þ 0.2 Wmoles), suggesting
that apoE isolated from the conditioned medium of
astrocytes has an e¡ect similar to circulating apoE.
The synergistic e¡ect of apoE on PIC-induced NO
production, the ability of apoE to interact with two
distinct types of in£ammatory agents (LPS and PIC)
and the apparent lack of an e¡ect of apoE on iNOS
protein expression suggested that apoE could poten-
tially regulate multiple components of the NO bio-
synthetic pathway. One alternate component is argi-
nine (substrate) availability. Activity of iNOS, NO
production and macrophage cytotoxicity are tightly
regulated by extracellular arginine availability [9,34^
37]. To determine if apoE altered the relationship
between extracellular arginine concentration and
NO production and thus, altered the availability of
substrate for iNOS enzymatic activity, we measured
NO production at varying concentrations of extra-
Fig. 3. Comparison of NO production. IFNQ-primed RAW cells
were treated for 24 h with PIC (0.5 Wg/ml) plus apoE (50 nM)
isolated from human plasma, with PIC (0.5 Wg/ml) plus apo-
lipoprotein B (50 nM) isolated from human plasma or with
LPS (0.1 Wg/ml) plus 50 nM apoE. Data points represent the
average percent of control þ S.E.M. obtained from 100U the
ratio of the experimental nitrite level to the nitrite level in PIC
(or LPS)-treated cells (PIC or LPS alone = 100%). (n) = number
of wells assayed. *P6 0.02; **P6 0.001.
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cellular arginine in IFNQ-primed RAW cells treated
with PIC alone (0.5 Wg/ml) and in combination with
apoE (50 nM). As shown in Fig. 4, supernatant ni-
trite levels increased with increasing extracellular ar-
ginine concentration under both treatment condi-
tions, reaching a maximum at approx. 1 mM
arginine. Treatment with apoE plus PIC, however,
signi¢cantly increased nitrite levels at submaximal
arginine concentrations compared to PIC alone.
One way to modify the relationship between extra-
cellular arginine levels and NO production is to in-
crease the uptake of arginine across the plasma mem-
brane and into the intracellular compartment.
Arginine uptake across the plasma membrane in
macrophages is dependent on the activity of system
y transporters, also known as cationic amino acid
transporters (CAT) [36,38^41]. To determine if apoE
altered arginine transport across the plasma mem-
brane in RAW cells, we examined the e¡ect of
apoE on [3H]arginine uptake. For these experiments,
cells were pretreated with 100 U/ml IFNQ in normal
medium for 8 h and then equilibrated for an addi-
tional 4 h in medium containing varying concentra-
tions of arginine (10^100 WM) in the presence of
apoE alone, PIC alone or apoE plus PIC. Arginine
uptake across the plasma membrane was then deter-
mined for each of the experimental conditions over a
range of extracellular arginine concentrations. As
shown in Fig. 5, IFNQ priming increased arginine
uptake compared to non-primed, untreated RAW
cells. Treatment of IFNQ-primed cells with PIC fur-
ther enhanced arginine uptake. However, simultane-
ous treatment with PIC and apoE produced the
greatest increase in arginine transport. No signi¢cant
change in arginine uptake was observed in IFNQ-
primed cells treated with apoE alone (Fig. 5) or in
primed cells treated with apolipoprotein B (apoB)
plus PIC (data not shown). Average values for the
apparent Vmax and the a⁄nity constant, KP, under
the above conditions are shown in Table 1. Treat-
ment with PIC plus apoE signi¢cantly increased the
Fig. 5. Arginine uptake across the plasma membrane in apoE-treated RAW cells. RAW cells were primed with IFNQ for 12 h or re-
mained untreated. These cells were then treated for an additional 4 h with medium containing varying concentrations of arginine in
the presence or absence of 50 nM apoE, 0.5 Wg/ml PIC or 50 nM apoE plus 0.5 Wg/ml PIC. 3H-Arginine uptake was then deter-
mined as described in Section 2. Data are presented as percent of control uptake (average þ S.E.M., n = 11^16 wells assayed per exper-
imental condition) and were determined from the ratio of the speci¢c arginine uptake (cpm/mg protein) under experimental conditions
to the speci¢c arginine uptake (cpm/mg protein) under non-primed (resting) conditions ( = 100%). P6 0.001 for PIC-treated compared
to IFNQ-primed only and P6 0.02 for PIC+apoE-treated compared to PIC-treated conditions using ANOVA.
Fig. 4. The e¡ect of extracellular arginine concentration on NO
production. IFNQ-primed RAW cells were treated for an addi-
tional 8 h in medium containing various concentrations of argi-
nine plus 0.5 Wg/ml PIC or 0.5 Wg/ml PIC plus 50 nM apoE.
Data points represent the average level of supernatant nitrite/Wg
protein þ S.E.M. (n) = ¢ve wells assayed. *P6 0.01 compared
to PIC alone; **P6 0.001 compared to PIC alone.
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maximal arginine transport and lowered KP com-
pared to IFNQ-primed untreated cells or compared
to IFNQ-primed, PIC-treated cells. Thus, our data
demonstrate that apoE in combination with PIC in-
duces a change in both maximal transport and trans-
porter a⁄nity for arginine.
Using semiquantitative RT-PCR [42,43], we also
determined the expression of mRNA for CAT1,
CAT2 and CAT3 in non-primed (resting) RAW cells
and in RAW cells treated as described above. Under
non-primed conditions, mRNA was detected for
CAT1 (Fig. 6A,B) but not for CAT2 (Fig. 6A,C).
IFNQ-primed cells, IFNQ-primed cells treated with
apoE or IFNQ-primed cells treated with PIC dis-
Fig. 6. (A) Expression of CAT transporter mRNA in RAW cells treated with apoE. RAW cells were non-primed or primed for 8 h
with IFNQ (100 U/ml) and then treated for 4 h with PIC (0.5 Wg/ml), PIC plus apoE (50 nM) or apoE alone (50 nM). Semiquantita-
tive RT-PCR was used to probe expression of the mRNAs for CAT1, CAT2 or CAT 3. Data are representative for one out of three
separate groups of RAW cells. (B) Relative expression of CAT1 mRNA. Densitometry was used to determine the average density of
each mRNA band for each experimental condition. The data represent the average ratio of the density ( þ S.E.M., n = 3) for CAT1
mRNA to the density for L-actin mRNA in the same sample. *P6 0.01 compared to other treatment conditions. (C) Relative expres-
sion for CAT2 mRNA. The data represent the average ratio of the density for CAT2 mRNA to L-actin mRNA for each experimental
condition. n = three separate cell groups. *P6 0.03 compared to other treatment conditions.
Table 1
Changes in arginine transport maximum and a⁄nity
IFNQ-primed untreated IFNQ-primed apoE IFNQ-primed PIC IFNQ-primed apoE+PIC
Vmax 95.7 þ 15 118.7 þ 25.4 110.9 þ 2.5* 144.0 þ 5.6**
KP 71.9 þ 22 105 þ 38.5 25.3 þ 1.6* 19 þ 2.1**
Average values were determined from a non-linear regression analysis on non-transformed data (Graph Pad Prism). (n) = ¢ve separate
experiments with ¢ve wells per experiment. *P6 0.02 compared to IFNQ-primed, apoE+PIC; **P6 0.04 compared to IFNQ-primed,
untreated.
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played measurable levels of CAT1 and CAT2
mRNA (Fig. 6A^C). However, simultaneous treat-
ment with PIC and apoE signi¢cantly increased the
relative expression of CAT2 mRNA while apparently
reducing the levels of CAT1 mRNA (Fig. 6A^C). A
signal corresponding to CAT3 mRNA expression
was not observed in RAW cells under any of the
treatment conditions.
4. Discussion
We previously reported that exogenous application
of apoE to human MDM induced a signi¢cant in-
crease in NO production [8]. This e¡ect has now
been observed in human microglia, rodent microglia,
murine peritoneal macrophages and murine macro-
phage clonal cells lines such as the RAW cells used
here [44]. Our new data further support a role for
apoE in the innate immune response mediated by
macrophages and particularly in the regulation of
nitric oxide production. For example, the ability of
apoE to increase NO production in RAW cells is
tightly linked to lymphokine-mediated (IFNQ or
IFNK) activation. Both IFNQ and IFNK increase
the functional responses of macrophages and fre-
quently act in concert with other cytoactive factors
to induce tissue defense mechanisms such as NO
production [12,22,29]. IFNQ priming facilitates the
action of apoE on NO production in RAW cells.
ApoE also works in concert with other macrophage
activating agents like LPS, a bacterial coat compo-
nent, or PIC, a viral mimetic, which are well known
to induce iNOS mRNA and protein expression,
iNOS enzymatic activities and to increase NO levels
[9,12,13,29,45,46]. We now show that ApoE potenti-
ated the action of either LPS or PIC in a dose-de-
pendent fashion. The e¡ect is speci¢c to apoE since
treatment of the RAW cells with another apolipopro-
tein, apoB, or with heat-inactivated (boiled) apoE
did not alter supernatant nitrite levels from non-lipo-
protein-treated controls.
We also examined the e¡ect of apoE isolated from
astrocyte CM on NO production. Astrocytes are the
primary source of apoE in the CNS [31,32,47] and
release a form of lipoprotein which di¡ers in lipid
content and structure compared to circulating apoE
[30]. Sun et al. [33] have characterized apoE isolated
from primary cultures of astrocytes derived from
mice made transgenic for human APOE3 on a mouse
APOE null background. Treatment of RAW cells
with this form of apoE3 produced a similar e¡ect
as the apoE puri¢ed from human plasma, suggesting
that the lipoprotein site which interacts with the mac-
rophage is conserved in both forms and that lipid
content is not a critical limiting factor.
ApoE-induced modulation of NO production can
occur at several points in the biosynthetic pathway.
The most common mechanism for regulation of mac-
rophage NO is via the induction of the iNOS gene
and the consequent expression of iNOS mRNA and
protein [9,11,46,48]. Consistent with previously pub-
lished ¢ndings [14,28,46,49], our data demonstrate
that treatment with PIC induces iNOS protein ex-
pression in macrophages. However, the apparent
lack of an e¡ect of apoE on iNOS protein expression
in PIC-treated cells was surprising and suggested the
possibility of alternate mechanisms for regulation of
NO. Further support for alternate sites of action was
provided by other data. For example, the level of
nitrite produced by the combination of PIC and
apoE is greater than that level expected from an
additive e¡ect of PIC and apoE alone. Furthermore,
the combination of apoE and PIC increased NO
production in the RAW cells at submaximal arginine
concentrations compared to PIC alone. The resultant
shift in the arginine-NO curve is similar to those
changes seen when arginase, an intracellular enzyme
that competes with iNOS for arginine, is inhibited
[35]. While this does not rule out a synergistic e¡ect
of apoE and PIC on induction of iNOS mRNA and
protein, our data are consistent with increased sub-
strate (arginine) availability for iNOS and hence, for
NO production. Finally, apoE has been shown to
a¡ect NO production in cells that contain cNOS in-
stead of iNOS. Riddell et al. [50] recently demon-
strated that inhibition of platelet aggregation by
apoE is mediated by NO. The similar overall e¡ect
of apoE on disparate cell types and NOS subtypes
further suggests a potential novel site of action for
apoE.
Arginine transport across the plasma membrane
was considered a likely candidate for modulation
by apoE since arginine availability is rate limiting
for NO production [9,34,36,51,52]. Macrophage argi-
nine uptake is mediated by a family of Na-inde-
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pendent, temperature-sensitive cationic transporters
known as the system y transporters or, more re-
cently, as the CAT transporters [36,40,53]. Of the
three subtypes of CAT proteins, CAT2 is associated
with activated macrophages, including RAW cells,
and is induced by LPS or other in£ammatory medi-
ators [36,39,40,53^55]. Kakuda et al. [53] and Stevens
et al. [56] have further demonstrated that CAT2 ex-
pression is linked with iNOS mRNA and protein
expression and NO production, suggesting that this
transporter is a major factor in the pathway for NO
synthesis during the innate immune response. Con-
sistent with these previously published ¢ndings
[40,53,56], we have demonstrated the presence of an
arginine uptake process with characteristics of system
y transporters in RAW cells. Our data further dem-
onstrate that viral mimics such as PIC increase trans-
port of arginine in IFNQ-primed cells and that apoE
enhances this process compared to PIC alone. This
e¡ect was seen over a physiological range of arginine
concentration, is within the concentration range of
apoE found in the CNS [6] and was speci¢c for
apoE since treatment with PIC plus apoB did not
produce a similar increase in arginine transport.
ApoE’s action on arginine transport may be ex-
plained, in part, by a change in the relative expres-
sion of CAT2 transports. Kakuda et al. [53,57] ob-
served a decrease in mRNA for CAT1 concomitant
with an increase in mRNA expression for CAT2 in
LPS-activated macrophages. We observed a similar
change in mRNA for CAT1 and CAT2 in RAW cells
primed with IFNQ alone, or in IFNQ-primed cells
treated with PIC or apoE alone. The combination
of PIC and apoE, however, was associated with a
large, relative increase in mRNA for CAT2 while
CAT1 mRNA levels were undetectable under the
same conditions. It is not clear how this dramatic
switch in mRNA from CAT1 to CAT2 translates
to a change in transport protein expression or to a
change in NO production. Kinetic analysis of these
transporters has shown a remarkable similarity be-
tween the two subtypes although small di¡erences in
apparent Vmax and arginine a⁄nity are observed [40].
Regardless, this type of change is clearly part of the
response of a macrophage to in£ammation and in-
jury and opens new avenues for further investigation.
The modulation of macrophage arginine transport
and, consequently, of NO production by apoE is a
novel regulatory mechanism for an apolipoprotein.
Our data suggest that the interaction between CAT
transporters, NO and apoE may underlie a basic
component of the tissue response to injury. This in-
terrelationship may be of importance in disease pro-
cesses such as chronic neurodegeneration where im-
mune activation, oxidative stress and apolipoprotein
E are known to play a role [18,58^61].
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